Paxmedica secures immediate exercise of warrants

Tarrytown, ny / accesswire / september 3, 2024 / paxmedica, inc. (otc pink:pxmd), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in november 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. the shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on form s-1 (no.
PXMD Ratings Summary
PXMD Quant Ranking